Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
| Status: | Completed |
|---|---|
| Conditions: | Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 21 - 70 |
| Updated: | 12/28/2013 |
| Start Date: | September 2013 |
| End Date: | September 2014 |
| Contact: | Pfizer CT.gov Call Center |
| Phone: | 1-800-718-1021 |
A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenous Doses Of Pf-05231023 In Obese Adult Subjects
This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and
pharmacodynamics of multiple doses of PF-05231023.
pharmacodynamics of multiple doses of PF-05231023.
Inclusion Criteria:
- Male and female subjects of non-childbearing potential between the ages of 21 and 70.
- Subjects with a BMI of 30 to 45.4 kg/m2 and total body weight >110 lbs.
Exclusion Criteria:
- Recent (6 months) unstable concurrent disease.
- History of allergic disease or drug allergies.
- Any condition affecting food consumption or absorption.
We found this trial at
1
site
Click here to add this to my saved trials
